Organization (Other)
Shandong New Time Pharmaceutical Co., LTD
ClinicalTrials.gov lists Shandong New Time Pharmaceutical Co., LTD as lead sponsor of 35 trials. It has 43 active development programs and 8 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 4 in 2026 and about 5 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
This page covers Shandong New Time Pharmaceutical Co., LTD: 35 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (24)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Multiple Myeloma | 3 |
| Recurrence | 3 |
| Atrial Fibrillation | 2 |
| Lymphoma | 2 |
| Uterine Cervical Neoplasms | 2 |
Showing 5 of 24 disease areas.
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 6 |
| 2024 | 6 |
| 2023 | 3 |
| 2022 | 7 |
| 2021 | 3 |
| 2020 | 5 |
| 2019 | 1 |
| 2017 | 1 |
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (43)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Valsartan Oral Solution | Hypertension | Phase 3 | 1 |
| Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd) | Multiple Myeloma | Phase 3 | 1 |
| Valsartan Oral Solution | Essential Hypertension | Phase 3 | 1 |
| Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd) | Recurrence | Phase 3 | 1 |
| F182112 single-agent | Multiple Myeloma | Phase 3 | 1 |
Showing 5 of 43 active programs.
Approved assets (8)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Huazhi Rougan granule | 1 |
| Semaglutide | 1 |
| CARBOPLATIN | 1 |
| (nab)-paclitaxel | 1 |
| PEMETREXED | 1 |
Showing 5 of 8 approved assets.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 4 | 3 | 2025-11-11 |
Latest dated events (39)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-11 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-10-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 39 events.
Biomarker capability evidence (200)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
| ARHGEF5 | Trial sponsor | Named in trial inclusion criteria |
| CD38 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 200 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, journals published in, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.